(1)

ea0072p1 | (1)

Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0

ea0072p2 | (1)

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) – UK and Ireland vs global diagnosis of NETs

ea0072p3 | (1)

Circulating biomarkers to predict progression-free survival in patients with neuroendocrine tumours received ¹⁷⁷Lu-DOTATATE

ea0072p4 | (1)

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

ea0072p5 | (1)

Allelic deletion of chromosome 18 is common in intra-abdominal neuroendocrine neoplasms

ea0072p6 | (1)

Metachronous neuroendocrine neoplasms in England 2013–2015

ea0072p7 | (1)

Carcinoid heart surgery: Review of outcomes from a single large centre

ea0072p8 | (1)

The prevalence of depression and anxiety among neuroendocrine tumour and general gastroenterology outpatients and the psychometric validity of emotional thermometers

ea0072p9 | (1)

Zoom-ing in on natters: Neuroendocrine cancer UK (NCUK) patient support groups during COVID pandemic

ea0072p10 | (1)

Are outcomes of patients with advanced well-differentiated GEP-NETs on somatostatin analogues similar, irrespective of tracer uptake on ⁶⁸gallium DOTA SSTR peptide PET CT scans?

ea0072p11 | (1)

The discontinuation of interferon-alfa for the treatment of metastatic NET: A case amongst many of poorer patient outcomes?

ea0072p12 | (1)

A new diagnosis of both a pituitary TSH-oma and a metastaticneuroendocrine tumour

ea0072p13 | (1)

Well-differentiated Gastroenteropancreatic G3 NET: Findings from a large single centre cohort

ea0072p14 | (1)

Effective multimodality therapy for a metastatic insulin-secreting pancreatic neuroendocrine tumour (NET): A case report

ea0072p15 | (1)

Specialist dietetic input in the south wales NET clinic: Patient outcomes

ea0072p16 | (1)

Endocrine Abstracts

UKI NETS 18th National Conference

Poster Presentations

Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0

Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor (NET) patients (SCAN) – UK and Ireland vs global diagnosis of NETs

Circulating biomarkers to predict progression-free survival in patients with neuroendocrine tumours received ¹⁷⁷Lu-DOTATATE

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

Allelic deletion of chromosome 18 is common in intra-abdominal neuroendocrine neoplasms

Metachronous neuroendocrine neoplasms in England 2013–2015

Carcinoid heart surgery: Review of outcomes from a single large centre

The prevalence of depression and anxiety among neuroendocrine tumour and general gastroenterology outpatients and the psychometric validity of emotional thermometers

Zoom-ing in on natters: Neuroendocrine cancer UK (NCUK) patient support groups during COVID pandemic

Are outcomes of patients with advanced well-differentiated GEP-NETs on somatostatin analogues similar, irrespective of tracer uptake on ⁶⁸gallium DOTA SSTR peptide PET CT scans?

The discontinuation of interferon-alfa for the treatment of metastatic NET: A case amongst many of poorer patient outcomes?

A new diagnosis of both a pituitary TSH-oma and a metastaticneuroendocrine tumour

Well-differentiated Gastroenteropancreatic G3 NET: Findings from a large single centre cohort

Effective multimodality therapy for a metastatic insulin-secreting pancreatic neuroendocrine tumour (NET): A case report

Specialist dietetic input in the south wales NET clinic: Patient outcomes

Mixed neuroendocrine-non-endocrine neoplasms (MiNEN): A case of pancreatic acinar – neuroendocrine carcinoma of large cell type

BiosciAbstracts